Cited by 215Cancer-related Molecular PathwaysGenetics, Aging, and Longevity in Model OrganismsTelomeres, Telomerase, and Senescence

Relevance of the p53–MDM2 axis to aging

Open access
Wu, Danyi, Prives, Carol·2018·Cell Death & Differentiation

Abstract

In response to varying stress signals, the p53 tumor suppressor is able to promote repair, survival, or elimination of damaged cells - processes that have great relevance to organismal aging. Although the link between p53 and cancer is well established, the contribution of p53 to the aging process is less clear. Delineating how p53 regulates distinct aging hallmarks such as cellular senescence, genomic instability, mitochondrial dysfunction, and altered metabolic pathways will be critical. Mouse models have further revealed the centrality and complexity of the p53 network in aging processes. While naturally aged mice have linked longevity with declining p53 function, some accelerated aging mice present with chronic p53 activation, whose phenotypes can be rescued upon p53 deficiency. Further, direct modulation of the p53-MDM2 axis has correlated elevated p53 activity with either early aging or with delayed-onset aging. We speculate that p53-mediated aging phenotypes in these mice must have (1) stably active p53 due to MDM2 dysregulation or chronic stress or (2) shifted p53 outcomes. Pinpointing which p53 stressors, modifications, and outcomes drive aging processes will provide further insights into our understanding of the human aging process and could have implications for both cancer and aging therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2017.187

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Development of MDM2/MDMX dual-target inhibitors may solve the problems existing in clinical research of MDM2 inhibitors and has great practical significance for treatment of related tumors.

    “It seems that the development of MDM2/MDMX dual-target inhibitors may solve the problems existing in the clinical research of the above MDM2 inhibitors and has great practical significance for the treatment of related tumors [97, 108, 109].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 65

  1. Kaeberlein M, Rabinovitch PS, Martin GM. Healthy aging: the ultimate preventative medicine. Science 2015; 350: 1191-1193.
  2. Passarino G, Montesanto A, De Rango F, Garasto S, Berardelli M, Domma F et al. A cluster analysis to define human aging phenotypes. Biogerontology 2007; 8: 283-290.
  3. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
  4. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
  5. Linskens MH, Harley CB, West MD, Campisi J, Hayflick L. Replicative senescence and cell death. Science 1995; 267: 17.
  6. Karni-Schmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer. Annu Rev Pathol 2016; 11: 617-644.
  7. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
  8. Poyurovsky MV, Prives C. P53 and aging: a fresh look at an old paradigm. Aging (Albany NY) 2010; 2: 380-382.
  9. Malkin D, Li FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
  10. Bhattacharya S, Chaum E, Johnson DA, Johnson LR. Age-related susceptibility to apoptosis in human retinal pigment epithelial cells is triggered by disruption of p53-Mdm2 association. Invest Ophthalmol Vis Sci 2012; 53: 8350-8366.
  11. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000; 97: 6763-6768.
  12. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, Killick R. p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett 2007; 418: 34-37.
  13. Checler F, Alves da Costa C. p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther 2014; 142: 99-113.
  14. Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR, Sanchez LM et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005; 437: 564-568.
  15. Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK et al. Dysfunction of the MDM2/p53 axis is linked to premature aging. J Clin Invest 2017; 127: 3598-3608.
  16. Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007; 104: 16633-16638.
  17. Tavernarakis N, Pasparaki A, Tasdemir E, Maiuri MC, Kroemer G. The effects of p53 on whole organism longevity are mediated by autophagy. Autophagy 2008; 4: 870-873.
  18. Bauer JH, Chang C, Morris SN, Hozier S, Andersen S, Waitzman JS et al. Expression of dominant-negative Dmp53 in the adult fly brain inhibits insulin signaling. Proc Natl Acad Sci USA 2007; 104: 13355-13360.
  19. Bauer JH, Poon PC, Glatt-Deeley H, Abrams JM, Helfand SL. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span. Curr Biol 2005; 15: 2063-2068.
  20. Arum O, Johnson TE. Reduced expression of the Caenorhabditis elegans p53 ortholog cep-1 results in increased longevity. J Gerontol A Biol Sci Med Sci 2007; 62: 951-959.
  21. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28: 128-136.
  22. Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene 2016; 35: 5713-5721.
  23. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ 2013; 20: 31-42.
  24. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-484.
  25. Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, Back P et al. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev 2008; 22: 3236-3241.
  26. Yee C, Yang W, Hekimi S. The intrinsic apoptosis pathway mediates the pro-longevity response to mitochondrial ROS in C. elegans. Cell 2014; 157: 897-909.
  27. Mesquita A, Weinberger M, Silva A, Sampaio-Marques B, Almeida B, Leao C et al. Caloric restriction or catalase inactivation extends yeast chronological lifespan by inducing H2O2 and superoxide dismutase activity. Proc Natl Acad Sci USA 2010; 107: 15123-15128.
  28. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
  29. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-159.
  30. Sahin E, DePinho RA. Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol 2012; 13: 397-404.
  31. Feng Z, Lin M, Wu R. The regulation of aging and longevity: a new and complex role of p53. Genes Cancer 2011; 2: 443-452.
  32. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102: 8204-8209.
  33. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003; 299: 572-574.
  34. Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 2003; 100: 8247-8252.
  35. Usui I, Imamura T, Huang J, Satoh H, Shenoy SK, Lefkowitz RJ et al. beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1. Mol Cell Biol 2004; 24: 8929-8937.
  36. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013; 32: 5129-5143.
  37. p53, Mdm2, and aging D Wu and C Prives 54. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
  38. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation- induced G1 arrest. Cell 1994; 76: 1013-1023.
  39. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53- dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-2551.
  40. van Deursen JM. The role of senescent cells in ageing. Nature 2014; 509: 439-446.
  41. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-551.
  42. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY) 2009; 1: 402-411.
  43. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010; 5: 99-118.
  44. Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 2014; 35: 1680-1690.
  45. Vicente R, Mausset-Bonnefont AL, Jorgensen C, Louis-Plence P, Brondello JM. Cellular senescence impact on immune cell fate and function. Aging Cell 2016; 15: 400-406.
  46. Ohkusu-Tsukada K, Tsukada T, Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 1999; 163: 1966-1972.
  47. Munoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 2016; 16: 741-750.
  48. Menendez D, Shatz M, Resnick MA. Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol 2013; 25: 85-92.
  49. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013; 210: 2057-2069.
  50. Zitvogel L, Kroemer G. CANCER. A p53-regulated immune checkpoint relevant to cancer. Science 2015; 349: 476-477.
  51. Yoon KW, Byun S, Kwon E, Hwang SY, Chu K, Hiraki M et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 2015; 349: 1261669.
  52. Cao L, Li W, Kim S, Brodie SG, Deng CX. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 2003; 17: 201-213.
  53. Vogel H, Lim DS, Karsenty G, Finegold M, Hasty P. Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci USA 1999; 96: 10770-10775.
  54. Lim DS, Vogel H, Willerford DM, Sands AT, Platt KA, Hasty P. Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol Cell Biol 2000; 20: 3772-3780.
  55. Pan D, Zhu Q, Conboy MJ, Conboy IM, Luo K. SnoN activates p53 directly to regulate aging and tumorigenesis. Aging Cell 2012; 11: 902-911.
  56. Murga M, Bunting S, Montana MF, Soria R, Mulero F, Canamero M et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 2009; 41: 891-898.
  57. Begus-Nahrmann Y, Lechel A, Obenauf AC, Nalapareddy K, Peit E, Hoffmann E et al. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere- dysfunctional mice. Nat Genet 2009; 41: 1138-1143.
  58. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002; 21: 6225-6235.
  59. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006; 20: 16-21.
  60. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004; 18: 306-319.
  61. Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev 2007; 128: 717-730.
  62. Meek DW. Regulation of the p53 response and its relationship to cancer. Biochem J 2015; 469: 325-346.
  63. Liu D, Ou L, Clemenson GD Jr., Chao C, Lutske ME, Zambetti GP et al. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol 2010; 12: 993-998.
  64. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12: 355-366.
  65. Boesten LS, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EA et al. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53- mediated caspase-3-independent cell death. Cell Death Differ 2006; 13: 2089-2098.

Cited by

Sorted by citations

Authors
Wu, D., & Prives, C.
Affiliations
Columbia University (US)
Corresponding author
Prives, Carol
Venue
Cell Death & Differentiation
Published
2017-12-01
Volume
25
Issue
1
Pages
169-179
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2774396895
Cited by
215
References
41
Citations by year
2026: 12 · 2025: 29 · 2024: 21 · 2023: 33 · 2022: 34 · 2021: 24 · 2020: 39 · 2019: 15 · 2018: 7 · 2017: 1
FWCI
1.78
Type
journal article
Language
en
Open access
Locations
  • Cell Death and Differentiation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA058316, CA 58316)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
p53, MDM2, aging, cellular senescence, genomic instability, mitochondrial dysfunction, metabolic aging, accelerated aging, p53 deficiency, stress response, longevity, cancer therapeutics
MeSH terms
Aging, Animals, Humans, Longevity, Neoplasms, Tumor Suppressor Protein p53, Aging, Premature, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review